Nivalis Therapeutics Inc. shares fell in the extended session Monday after the drug developer said its cystic fibrosis drug failed to reach endpoints in a clinical trial. Nivalis shares, which had been briefly halted, fell 56% to $2.73 after hours. The company said a mid-stage clinical study of its drug cavosonstat did not significantly improve lung function in cystic fibrosis patients when compared to a placebo.
Copyright © 2016 MarketWatch, Inc.
Continue Reading Below